Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC)

被引：0
|
作者：
Aqel, Osama
Shen, Yunrong
Alfayoumi, Ibrahim
Abraham, Ivo
机构：
[1] Univ Arizona, Ctr Hlth Outcomes & Pharmacoecon Res, Tucson, AZ USA
[2] Univ Arizona Pharm, Dept Pharm Practice & Sci, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [41] New drug approval: Durvalumab in combinaison with cisplatin and gemcitabine in first-line in patient with advanced biliary tract cancer
    Blondet, Laure
    Sarabi, Matthieu
    BULLETIN DU CANCER, 2023, 110 (7-8) : 742 - 744
  • [42] Population pharmacokinetics and exposure-response analysis of durvalumab in combination with gemcitabine and cisplatin in patients with advanced biliary tract cancer
    Abegesah, Aburough
    Oh, Do-Youn
    Lim, Kyoungsoo
    Fan, Chunling
    Chen, Cecil
    Kim, Chong
    Wang, Julie
    Xynos, Ioannis
    Zotkiewicz, Magdalena
    Ren, Song
    Phipps, Alex
    Gibbs, Megan
    Zhou, Diansong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2025, 95 (01)
  • [43] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Bouattour, Mohamed
    Valle, Juan W.
    Vogel, Arndt
    Kim, Jin Won
    Kitano, Masayuki
    Chen, Jen-Shi
    Burris, Howard A., III
    Zaucha, Renata
    Qin, Shukui
    Evesque, Ludovic
    Zhen, David Bing
    Gupta, Vineet Govinda
    Park, Joon Oh
    Zotkiewicz, Magdalena
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 531 - 531
  • [44] COST-EFFECTIVENESS OF GEMCITABINE PLUS CISPLATIN VERSUS GEMCITABINE ALONE FOR TREATMENT OF ADVANCED BILIARY TRACT CANCER IN JAPAN
    Arakawa, I
    Uemura, S.
    Murasawa, H.
    Inoue, T.
    VALUE IN HEALTH, 2013, 16 (07) : A416 - A416
  • [45] Patient-reported outcomes for the phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Burris, Howard A., III
    Okusaka, Takuji
    Vogel, Arndt
    Lee, Myung Ah
    Takahashi, Hidenori
    Breder, Valeriy Vladimirovich
    Blanc, Jean-Frederic
    Li, Junhe
    Watras, Magdalena
    Xiong, Julia
    Abraham, Jayne
    Patel, Nikunj
    Wang, Julie
    Rokutanda, Nana
    Cohen, Gordon
    Oh, Do-Youn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Clinical outcomes of gemcitabine, cisplatin plus S-1 in patients with advanced biliary tract cancer
    Niisato, Yusuke
    Ishida, Hiroyasu
    Onoda, Tsubasa
    Shimoyamada, Yudai
    Ito, Yuka
    Yamaguchi, Takashi
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer
    Valle, J. W.
    Kelley, R. K.
    Furuse, J.
    Edeline, J.
    Finn, R. S.
    Ren, Z.
    Su, S-C.
    Malhotra, U.
    Siegel, A. B.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S270 - S271
  • [48] EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN AS FIRST-LINE CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER
    Oka, Y.
    Todaka, A.
    Fukutomi, A.
    Tsushima, T.
    Yokota, T.
    Machida, N.
    Yamazaki, K.
    Onozawa, Y.
    Boku, N.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2013, 24 : 44 - 44
  • [49] Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Park, Byung Kyu
    Kim, Yoon Jae
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Chung, Jae Bock
    Kim, Kyung Sik
    Choi, Jin-Sub
    Lee, Woo Jung
    Song, Si Young
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 (06) : 999 - 1003
  • [50] A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer
    Kim, ST
    Park, JO
    Lee, J
    Lee, KT
    Lee, JK
    Choi, SH
    Heo, JS
    Park, YS
    Kang, WK
    Park, K
    CANCER, 2006, 106 (06) : 1339 - 1346
12345